OTCMKTS:OASMY Vivesto (OASMY) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free OASMY Stock Alerts $0.02 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0252-Week Range$0.00▼$0.02VolumeN/AAverage Volume7 shsMarket Capitalization$3.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendFinancialsSEC FilingsShort InterestStock AnalysisChartDividendFinancialsSEC FilingsShort Interest Get Vivesto alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Vivesto Stock (OTCMKTS:OASMY)Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.Read More OASMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OASMY Stock News HeadlinesApril 17, 2024 | americanbankingnews.comContrasting Vivesto (OTCMKTS:OASMY) & Galapagos (NASDAQ:GLPG)January 20, 2024 | morningstar.comVivesto AB ADR OASMYApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.August 29, 2023 | finance.yahoo.comVivesto AB (OASMY) Stock Historical Prices & Data - Yahoo FinanceJuly 19, 2023 | investing.comOMX Stockholm Pharmaceuticals and Biotechnology GI (SX201030GI)June 4, 2023 | investing.comOMX Stockholm Health Care GI (SX20GI)February 26, 2023 | benzinga.comGlobal Pet Cancer Therapeutics Market Report to 2027 - Featuring Zoetis, AB Science, Karyopharm Therapeutics, Vivesto and Merial Among OthersJanuary 11, 2022 | nasdaq.comOasmia Pharmaceutical AB ADR (OASMY)See More Headlines Receive OASMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivesto and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OASMY CUSIPN/A CIK1607245 Webwww.oasmia.com Phone(461) 850-5440Fax461-851-0873Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,350,000.00 Net MarginsN/A Pretax Margin-654,234.38% Return on Equity-99.73% Return on Assets-91.27% Debt Debt-to-Equity Ratio0.01 Current Ratio4.65 Quick Ratio4.65 Sales & Book Value Annual Sales$100,000.00 Price / Sales35.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.11Miscellaneous Outstanding Shares179,350,000Free FloatN/AMarket Cap$3.59 million OptionableNot Optionable Beta21.10 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Erik Kinnmann Assoc. Prof. (Age 66)M.B.A., M.D., Ph.D., Chief Executive Officer Mr. Robert Maiorana (Age 64)Head of Accounting & Acting CFO Mr. Kai Wilkinson (Age 43)Chief Technical Officer Mr. Urban EkelundIR ManagerMr. John T. Cosby (Age 62)Head of Regulatory Affairs Mr. Dzianis BabrouHead of Product DevelopmentMr. Henrik RönnbergChief Medical Officer of Animal HealthMaria Nilsson HagbergHead of Regulatory AffairsDr. Heidi B. Ramstad (Age 55)Chief Medical Officer Ms. Johanna Rostin (Age 57)Chief Regulatory Officer More ExecutivesKey CompetitorsAppili TherapeuticsOTCMKTS:APLIFGeoVax LabsNASDAQ:GOVXRevelation BiosciencesNASDAQ:REVBPhaseBio PharmaceuticalsNASDAQ:PHASSunshine BiopharmaNASDAQ:SBFMView All Competitors OASMY Stock Analysis - Frequently Asked Questions How have OASMY shares performed in 2024? Vivesto's stock was trading at $0.02 on January 1st, 2024. Since then, OASMY shares have increased by 0.0% and is now trading at $0.02. View the best growth stocks for 2024 here. How do I buy shares of Vivesto? Shares of OASMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OASMY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivesto AB Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
